SCHEMBL23970521

SCHEMBL23970521

O=C1NC(Nc2ccc(F)cc2)=N/C1=C\c1ccc2ncsc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 16/20 1.00
▸ DYRK2 Q92630 16/20 1.00
▸ CLK1 P49759 15/20 1.00
▸ DYRK1B Q9Y463 15/20 1.00
▸ CLK4 Q9HAZ1 14/20 1.00
▸ DYRK3 O43781 13/20 1.00
▸ CLK2 P49760 12/20 1.00
▸ CLK3 P49761 9/20 1.00
▸ DYRK4 Q9NR20 8/20 1.00
▸ GSK3B P49841 6/20 0.81
▸ CSNK1E P49674 1/20 0.69
▸ CSNK2A2 P19784 5/20 0.60
▸ CSNK2B P67870 5/20 0.60
▸ CSNK2A1 P68400 5/20 0.60
▸ CSNK2A3 Q8NEV1 3/20 0.60
▸ PIM1 P11309 3/20 0.59
▸ CNR1 P21554 1/20 0.54
▸ CDK5 Q00535 1/20 0.47
▸ CDK5R1 Q15078 1/20 0.47
▸ PIK3CD O00329 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23510515 0.91 DYRK2 (0.84) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL29899824 0.91 DYRK2 (0.84) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL28843061 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL29899850 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL28843039 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL29899965 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL23510496 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL24904295 0.90 DYRK2 (0.81) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL23510450 0.89 DYRK1A (1.00) DYRK1ADYRK2CLK1DYRK1BCLK4
SCHEMBL29899879 0.89 DYRK1A (1.00) DYRK1ADYRK2CLK1DYRK1BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143185-B1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-10-29 — — EP claimed
EP-4143185-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-03-08 — — EP claimed
CN-115515953-A Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 珀哈制药公司 2022-12-23 — — CN claimed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 — — US disclosed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 — — US disclosed
EP-4143185-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-03-08 — — EP disclosed
CN-115515953-A Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 珀哈制药公司 2022-12-23 — — CN disclosed
EP-3904354-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2021-11-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 DYRK1A 18/4885DYRK2 88/4885CLK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback